Download MendeleyDiscovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.
Ma, C., Kang, D., Gao, P., Zhang, W., Wu, X., Xu, Z., Han, H., Zhang, L., Cai, Y., Wang, Y., Wang, Y., Long, W.(2024) J Med Chem 67: 13534-13549
- PubMed: 39110625
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00360
- Primary Citation of Related Structures:
8WX7 - PubMed Abstract:
As an oncogenic phosphatase, SHP2 acts as a converging node in the RTK-RAS-MAPK signaling pathway in cancer cells and suppresses antitumor immunity by passing signals downstream of PD-1. Here, we utilized the extra druggable pocket outside the previously identified SHP2 allosteric tunnel site by the (6,5 fused), 6 spirocyclic system. The optimized compound, JAB-3312 , exhibited a SHP2 binding K d of 0.37 nM, SHP2 enzymatic IC 50 of 1.9 nM, KYSE-520 antiproliferative IC 50 of 7.4 nM and p-ERK inhibitory IC 50 of 0.23 nM. For JAB-3312 , an oral dose of 1.0 mg/kg QD was sufficient to achieve 95% TGI in KYSE-520 xenograft model of mouse. JAB-3312 was well-tolerated in animal models, and a close correlation was observed between the plasma concentration of JAB-3312 and the p-ERK inhibition in tumors. Currently, JAB-3312 is undergoing clinical trials as a potential anticancer agent.
Organizational Affiliation:
Medicinal Chemistry, Jacobio Pharmaceuticals, Beijing 101111, China.
